Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Necrosis Factor-alpha | 5 | 2019 | 325 | 2.190 |
Why?
|
| Chemokine CCL2 | 4 | 2019 | 82 | 1.690 |
Why?
|
| Apigenin | 2 | 2019 | 12 | 1.340 |
Why?
|
| Allyl Compounds | 2 | 2015 | 47 | 1.010 |
Why?
|
| Disulfides | 2 | 2015 | 77 | 0.990 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 781 | 0.910 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 203 | 0.790 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 1426 | 0.690 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2017 | 137 | 0.670 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 162 | 0.630 |
Why?
|
| Interleukin-1alpha | 1 | 2017 | 17 | 0.610 |
Why?
|
| I-kappa B Kinase | 1 | 2017 | 40 | 0.590 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 600 | 0.570 |
Why?
|
| Microglia | 4 | 2018 | 152 | 0.540 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2015 | 13 | 0.540 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 756 | 0.430 |
Why?
|
| Cell Line, Tumor | 7 | 2019 | 2128 | 0.380 |
Why?
|
| Lipopolysaccharides | 6 | 2021 | 200 | 0.330 |
Why?
|
| Cytokines | 3 | 2017 | 569 | 0.330 |
Why?
|
| Hydrolyzable Tannins | 2 | 2018 | 14 | 0.320 |
Why?
|
| Interferon-gamma | 5 | 2020 | 235 | 0.300 |
Why?
|
| Biological Products | 2 | 2016 | 67 | 0.270 |
Why?
|
| Garlic | 2 | 2015 | 31 | 0.260 |
Why?
|
| Cell Survival | 6 | 2017 | 818 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2016 | 8 | 0.230 |
Why?
|
| Cell Proliferation | 3 | 2019 | 1149 | 0.220 |
Why?
|
| Macrophages | 2 | 2016 | 431 | 0.220 |
Why?
|
| Immunoglobulin E | 1 | 2021 | 54 | 0.200 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2021 | 58 | 0.200 |
Why?
|
| Salmonella Infections, Animal | 1 | 2020 | 1 | 0.190 |
Why?
|
| Mast Cells | 1 | 2021 | 77 | 0.190 |
Why?
|
| Salmonella typhimurium | 1 | 2020 | 40 | 0.190 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2020 | 41 | 0.190 |
Why?
|
| Chalcones | 1 | 2019 | 13 | 0.180 |
Why?
|
| High-Throughput Screening Assays | 2 | 2016 | 63 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 251 | 0.170 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 179 | 0.170 |
Why?
|
| Mice | 10 | 2021 | 5668 | 0.170 |
Why?
|
| Protein Array Analysis | 2 | 2017 | 26 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2009 | 117 | 0.160 |
Why?
|
| Humans | 12 | 2019 | 34853 | 0.160 |
Why?
|
| Liver | 1 | 2020 | 447 | 0.160 |
Why?
|
| Petroselinum | 1 | 2017 | 4 | 0.160 |
Why?
|
| Female | 7 | 2019 | 19873 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 120 | 0.150 |
Why?
|
| Chemokine CXCL2 | 1 | 2016 | 9 | 0.150 |
Why?
|
| Nitrogen Dioxide | 1 | 2016 | 10 | 0.150 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2017 | 59 | 0.150 |
Why?
|
| Lactic Acid | 1 | 2017 | 87 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 445 | 0.140 |
Why?
|
| Benzoquinones | 1 | 2016 | 34 | 0.140 |
Why?
|
| Gene Silencing | 1 | 2017 | 143 | 0.140 |
Why?
|
| Glioma | 1 | 2016 | 76 | 0.140 |
Why?
|
| Breast | 1 | 2017 | 134 | 0.140 |
Why?
|
| NF-kappa B | 1 | 2018 | 306 | 0.140 |
Why?
|
| Sepsis | 1 | 2016 | 76 | 0.140 |
Why?
|
| Pyridones | 1 | 2016 | 40 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 107 | 0.140 |
Why?
|
| Anthracenes | 1 | 2015 | 13 | 0.140 |
Why?
|
| Butadienes | 1 | 2015 | 30 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2015 | 20 | 0.130 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2015 | 31 | 0.130 |
Why?
|
| Triazoles | 1 | 2016 | 85 | 0.130 |
Why?
|
| Nitriles | 1 | 2015 | 66 | 0.130 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 93 | 0.130 |
Why?
|
| Nucleotides, Cyclic | 1 | 2014 | 6 | 0.130 |
Why?
|
| Enterotoxigenic Escherichia coli | 1 | 2014 | 5 | 0.130 |
Why?
|
| Anticarcinogenic Agents | 1 | 2015 | 65 | 0.130 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 391 | 0.130 |
Why?
|
| Imidazoles | 1 | 2015 | 124 | 0.130 |
Why?
|
| Enterotoxins | 1 | 2014 | 32 | 0.130 |
Why?
|
| Pyridines | 1 | 2015 | 113 | 0.130 |
Why?
|
| Apoptosis | 2 | 2014 | 1317 | 0.130 |
Why?
|
| Phosphorylation | 2 | 2015 | 878 | 0.130 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 44 | 0.130 |
Why?
|
| Animals | 11 | 2021 | 14307 | 0.120 |
Why?
|
| Adipokines | 1 | 2014 | 24 | 0.120 |
Why?
|
| Escherichia coli | 1 | 2016 | 436 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 355 | 0.120 |
Why?
|
| Escherichia coli Proteins | 1 | 2014 | 119 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 480 | 0.110 |
Why?
|
| Antioxidants | 1 | 2016 | 386 | 0.110 |
Why?
|
| Water | 1 | 2014 | 283 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2014 | 366 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 56 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 70 | 0.090 |
Why?
|
| Cell Line | 3 | 2018 | 1289 | 0.080 |
Why?
|
| Interferon-beta | 1 | 2008 | 7 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2017 | 1802 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2008 | 44 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 31 | 0.080 |
Why?
|
| Naphthalenes | 1 | 2008 | 37 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 106 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 984 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 1530 | 0.070 |
Why?
|
| Gene Expression | 1 | 2008 | 639 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2008 | 296 | 0.060 |
Why?
|
| Nitric Oxide | 2 | 2017 | 287 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2016 | 109 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 242 | 0.050 |
Why?
|
| Crystallography, X-Ray | 2 | 2016 | 237 | 0.050 |
Why?
|
| Drug Design | 2 | 2016 | 154 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2016 | 376 | 0.050 |
Why?
|
| GATA3 Transcription Factor | 1 | 2020 | 4 | 0.050 |
Why?
|
| Gallbladder | 1 | 2020 | 3 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2020 | 96 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2020 | 123 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2020 | 67 | 0.050 |
Why?
|
| Macrophage Activation | 1 | 2020 | 52 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2020 | 69 | 0.050 |
Why?
|
| Spleen | 1 | 2020 | 192 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2014 | 649 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2020 | 135 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2016 | 751 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2009 | 323 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 469 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2017 | 87 | 0.040 |
Why?
|
| Lipid Peroxides | 1 | 2016 | 16 | 0.040 |
Why?
|
| Glycolysis | 1 | 2017 | 66 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2017 | 91 | 0.040 |
Why?
|
| Superoxides | 1 | 2016 | 51 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2017 | 149 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2017 | 88 | 0.040 |
Why?
|
| Catalase | 1 | 2016 | 106 | 0.040 |
Why?
|
| Neutrophils | 1 | 2016 | 124 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2017 | 180 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2016 | 149 | 0.030 |
Why?
|
| Glutathione | 1 | 2016 | 160 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2016 | 181 | 0.030 |
Why?
|
| Rats | 2 | 2016 | 3261 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 430 | 0.030 |
Why?
|
| Glucose | 1 | 2017 | 217 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 528 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2016 | 77 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 968 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2017 | 420 | 0.030 |
Why?
|
| Corneal Neovascularization | 1 | 2008 | 6 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 58 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2008 | 79 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2008 | 81 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2008 | 69 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 269 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 162 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 212 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 298 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 605 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2008 | 467 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 901 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 1534 | 0.010 |
Why?
|
| Male | 2 | 2008 | 18870 | 0.010 |
Why?
|
| Adult | 1 | 2008 | 11034 | 0.010 |
Why?
|